Press Releases

Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores also known as herpes labialis or oral herpes, an illness caused by herpes simplex virus, usually type 1 (HSV-1). 

SQX770 is a unique, first in class topical immunomodulator. SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.